Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Procurement Technical Assistance Centers (PTACs) are an official government contracting resource for small businesses. Find your local PTAC (opens in new window) for free government expertise related to contract opportunities.

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) toestablish an eff ective, eff icient, integrated pharmacy benefits program for theMilitary Health System (MHS) which includes the purchase pharmaceuticalagents. The law and implementing regulation (32 CFR Section 199.21) describethe process by which the DoD Pharmacy and Therapeutics (P&T) Committee willconsider the relative clinical eff ectiveness and relative cost eff ectiveness ofpharmaceutical agents in a therapeutic class in recommending the selection ofagents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, theclassification of a pharmaceutical agent as generic, formulary, Basic CoreFormulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior tothe scheduled P&T Committee meeting, a Request for Quotation (RFQ) forpharmaceutical agents within Drug Classes identified for placement on the UFhas been issued to obtain quotes from industry. The Defense Health Agency mayaward Uniform Formulary Blanket Purchase Agreements (UF BPA) and theUniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: August 2023: The following drug classes/subclass will be reviewed:

a. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists – Subclass: Central Precocious Puberty Agents

Fensolvi

Lupron Depot-Ped

b. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists – Subclass: Endometriosis /Fibroids Agent

Lupron Depot 3.75mg & 11.25mg

Myfembree

Oriahnn

Orilissa

c. Luteinizing Hormone-Releasing Hormone Agonists-Antagonists – Subclass: Prostate Cancer Agents

Camcevi

Eligard

Firmagon

Lupron Depot 7.5mg, 22.5mg, 30mg, & 45mg

Leuprolide Acetate Injection Depot 22.5mg

Orgovyx

d. White Blood Cell Stimulants Subclass: Filgrastim

Granix

Neupogen

Nivestym

Releuko

Zarxio

e. White Blood Cell Stimulants Subclass: Pegfilgrastim

Fulphila

Fylnetra

Neulasta

Neulasta OnPro

Nyvepria

Stimufend

Udenyca

Ziextenzo

The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQHT9402-23-Q-9301.

Pre-proposal teleconference is on May 10, 2023, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.